Products
Lulizumab Biosimilar Single-Domain VL Antibody Fragment (CD28) for Research
Pre-Made Lulizumab biosimilar, Single Domain Variable Fragment;L, Anti-CD28 Antibody: Anti-Tp44 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lulizumab pegol (INN; development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases. This drug was developed by Bristol-Myers Squibb.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-326-1mg | 1mg | 3090 |
| GMP-Bios-ab-326-10mg | 10mg | |
| GMP-Bios-ab-326-100mg | 100mg | |
| GMP-Bios-ab-326-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lulizumab biosimilar, Single Domain Variable Fragment;L, Anti-CD28 Antibody: Anti-Tp44 therapeutic antibody |
| INN Name | Lulizumab |
| Target | CD28 |
| Format | Single Domain Variable Fragment;L |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | na |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Bristol-Myers Squibb |
| Conditions Approved | na |
| Conditions Active | Sjogren's syndrome;Systemic lupus erythematosus;Renal transplant rejection |
| Conditions Discontinued | na |
| Development Tech | na |
About target - CD28
1. Protein T-cell-specific surface glycoprotein CD28
2. Gene CD28
3. Organism Homo sapiens (Human)
Function
Involved in T-cell activation, the induction of cell proliferation and cytokine production and promotion of T-cell survival. Enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L costimulation (PubMed:8617933).
Isoform 3 enhances CD40L-mediated activation of NF-kappa-B and kinases MAPK8 and PAK2 in T-cells (PubMed:15067037).
